Peptides having anti-inflammatory properties
Inventors
Jaynes, Jesse M. • Lopez, Henry W. • Martin, George R. • YATES, Clayton • Garvin, Charles E.
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Riptide BioscienceRiptide Bioscience develops engineered peptides derived from host defense peptides found widely in nature. Their focus is on creating peptide-based therapeutics for cancer, inflammatory diseases, and microbial infections, especially those resistant to conventional treatments. The company advances both preclinical and early-stage clinical programs, collaborates with academic partners and government agencies, and holds patents for its engineered peptide design technologies.
Riptide Bioscience develops engineered peptides derived from host defense peptides found widely in nature. Their focus is on creating peptide-based therapeutics for cancer, inflammatory diseases, and microbial infections, especially those resistant to conventional treatments. The company advances both preclinical and early-stage clinical programs, collaborates with academic partners and government agencies, and holds patents for its engineered peptide design technologies.
Publication Number
US-9492499-B2
Publication Date
2016-11-15
Expiration Date
Abstract
Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.
Core Innovation
Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals. The present invention is based, in part, on the discovery of novel peptides that have powerful anti-inflammatory activities in vitro and in vivo. The present invention is also based, in part, on the discovery that peptides of the invention specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins, and that the peptides are sufficiently stable in the circulation to allow for intravenous administration.
Under normal conditions inflammation helps an animal recover from injury, but various agents can cause prolonged and excessive inflammation known as chronic inflammation, which contributes to many diseases and can lead to fibrosis. The result of chronic inflammation is the destruction of normal tissue and its replacement with collagen-rich connective tissue, and persistent formation of scar tissue leads to fibrosis implicated in idiopathic pulmonary fibrosis, scleroderma, keloids, liver cirrhosis, myocardial fibrosis, diabetic kidney disease and other disorders. Despite growing knowledge about conditions that involve excessive inflammation, treatments for such conditions remain elusive and many anti-inflammatory therapies are associated with harmful side effects, creating a critical need to identify therapeutic agents that reduce inflammation without harmful side effects.
Claims Coverage
One independent claim was identified. The extracted inventive feature focuses on an anti-inflammatory composition defined by specific peptide sequence(s).
Anti-inflammatory composition comprising specified peptide sequences
An anti-inflammatory composition comprising a peptide, wherein the peptide comprises one of the amino acid sequences selected from the group consisting of: SEQ ID NO: 121, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 120.
The independent claim covers an anti-inflammatory composition whose core inventive feature is a peptide selected from a defined list of SEQ ID NOs; dependent claims further specify binding properties, additional targets, formulations, and method-of-use features.
Stated Advantages
Peptides of the invention have powerful anti-inflammatory activities in vitro and in vivo.
Peptides of the invention specifically bind to key functional regions on signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins.
Peptides of the invention are sufficiently stable in the circulation to allow for intravenous administration.
Documented Applications
Compositions containing one or more peptides for treating conditions associated with excessive inflammation in animals, particularly humans and other mammals.
Methods of treating chronic inflammatory conditions such as irritable bowel disease, ulcerative colitis, colitis, Crohn's disease, fibrosis, idiopathic pulmonary fibrosis, asthma, keratitis, arthritis, osteoarthritis, rheumatoid arthritis, and auto-immune diseases.
Methods of treating or preventing fibrosis, including pulmonary fibrosis, dermal fibrosis, hepatic fibrosis, renal fibrosis, and fibrosis caused by ionizing radiation.
Methods of treating cancer, including use in combination with chemotherapeutic agents, immunotherapeutic agents, and/or radiation therapy; cancers explicitly listed include colon cancer, breast cancer, leukemia, lymphoma, ovarian cancer, prostate cancer, liver cancer, lung cancer, testicular cancer, cervical cancer, bladder cancer, endometrial cancer, kidney cancer, melanoma, and cancers of the thyroid or brain.
Pharmaceutical compositions comprising an anti-inflammatory polypeptide and a pharmaceutically acceptable carrier, including compositions comprising a single peptide or combinations of two or more peptides and compositions that include serum albumin.
Interested in licensing this patent?